GeneralConnection.com ➔ Dictionary
Dictionary Search

ritonavir

Synonyms

Noun

1. Norvir

2. protease inhibitor, PI

Usage
A study on the stability of ritonavir form III processed in orbit and returned to Earth | npj Microgravity - Nature
Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients - The New England Journal of Medicine
Nirmatrelvir/Ritonavir Reduces Risk of Hospitalization in At-Risk Outpatients - American Academy Of Family Physicians | AAFP
Nirmatrelvir-Ritonavir Significantly Lowers Risk for COVID-19-Related Hospitalization - Infectious Disease Advisor
Nirmatrelvir-Ritonavir Speeds COVID-19 Recovery but Fails to Reduce Hospitalizations in Vaccinated High-Risk Adults - Pharmacy Times
Nirmatrelvir/ritonavir use reduces risk for long COVID in patients with immunodeficiency - Rockefeller University Press
Cost-Effectiveness of Nirmatrelvir-Ritonavir Varies by COVID-19 Risk Profile - AJMC
The curious case of disappearing polymorphs - Chemistry World
13 Things To Know About Paxlovid, the COVID-19 Pill | News - Yale Medicine
Paxlovid doesn’t reduce hospitalization, death rates in vaccinated high-risk COVID outpatients, trial shows - CIDRAP
Boceprevir Label Revised: Do Not Coadminister With Ritonavir-Boosted HIV Protease Inhibitors - Gastroenterology & Endoscopy News
Predicting the ritonavir crisis by revisiting the polymorph landscape with crystal structure prediction and form 4 structure solution | Communications Chemistry - Nature
Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients - The New England Journal of Medicine
Nirmatrelvir/Ritonavir Reduces Hospitalization, Mortality in Patients 65 Years and Older With COVID-19; Effect on Younger Patients Unclear - American Academy Of Family Physicians | AAFP
Greater benefits of immediate nirmatrelvir-ritonavir initiation for post-COVID outcomes: a population-based retrospective cohort study - Nature
Should Patients with COVID-19 Who Are at Standard Risk Take Nirmatrelvir/Ritonavir? - NEJM Clinician
Nirmatrelvir/Ritonavir Does Not Significantly Reduce Symptoms or Hospitalization in Vaccinated High-Risk Patients and Unvaccinated Patients - American Academy Of Family Physicians | AAFP
Effectiveness of nirmatrelvir/ritonavir and molnupiravir in reducing the risk of short-term and long-term cardiovascular complications of COVID-19: a target trial emulation study - Nature
A real-world retrospective analysis comparing the effectiveness of Azvudine and Nirmatrelvir/Ritonavir in COVID-19 patients with diabetes - Nature
Drug-related problems and challenges encountered by pharmacists in nirmatrelvir/ritonavir counselling during the covid-19 pandemic: a multi-center study - Nature
Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial - The Lancet
Molnupiravir, Nirmatrelvir-Ritonavir Not Supported for Inpatients With COVID-19 - Vaccine Advisor
If It's COVID, Paxlovid? Studies Suggest a Rethink These Days - MedPage Today
Nirmatrelvir-Ritonavir Has Variable Impact on Incidence of Post-COVID-19 Condition - Pharmacy Times
Paxlovid speeds recovery but does not reduce severe COVID outcomes in vaccinated adults - News-Medical
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - The Lancet
Based a Machine Learning Approach to Investigate the Factors Influencing Nirmatrelvir/ritonavir Exposure in Human Plasma: A Multicenter, Observational Study - Frontiers
Pharmacokinetic drug-drug interaction between the COVID-19 3CL protease inhibitor GST-HG171 and itraconazole in healthy subjects - ASM Journals
Trials demonstrate Paxlovid’s evolving role against COVID-19 - Healio
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 - The New England Journal of Medicine
Varda Deepens Drugs-in-Space Bet After Win With AIDS Medication - Bloomberg.com
Trial data show ensitrelvir has potent antiviral activity against COVID-19 - CIDRAP
Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19 - The New England Journal of Medicine
Pharmacokinetics, pathology and efficacy of SARS-CoV-2 main protease inhibitor VPC285785 in a murine model of coronavirus infection - Nature
Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation - Nature
Profound Synergistic Bradycardia: Pharmacokinetic Consequences of Paxlovid-Mediated CYP3A4 and CYP2D6 Inhibition on Ranolazine, Diltiazem, and Metoprolol - Cureus
VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19 - The New England Journal of Medicine
Exploring the therapeutic mechanism of itraconazole combined with ritonavir on Candida albicans infection through network pharmacology and molecular docking - Frontiers
10 Common Ritonavir Interactions You Want to Watch for - GoodRx
Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients - Nature
Antiretroviral therapy and associated drug interactions with cardiovascular drugs: a critical review - Frontiers
Complete Heart Block Triggered by Nirmatrelvir-Ritonavir and Verapamil: - JACC Journals
Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation - Nature
Nirmatrelvir Speeds Recovery, Cuts Symptoms in COVID-19 - Medscape
Microgravity Is The Final Frontier For Medicine. Here's Why. - ScienceAlert
Paxlovid substantially reduced risk of hospitalization, death during Omicron wave - Hospital News
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial - The Lancet
Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study - Nature
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV - Nature
Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12–17 years following SARS-CoV-2 Omicron infection: A target trial emulation - Nature
Stability indicating RP-HPLC technique for simultaneous estimation of nirmatrelvir and ritonavir in their new copackaged dosage form for COVID-19 treatment - Nature
Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial - The Lancet
Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system - The Lancet
Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study - The Lancet
Predictors of nirmatrelvir–ritonavir receipt among COVID-19 patients in a large US health system - Nature
AustralaSian COVID-19 Trial (ASCOT) removes hydroxychloroquine and lopinavir/ritonavir arms of the trial - Doherty Institute
Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19 - Nature
The effect of nirmatrelvir-ritonavir on hospital admissions and mortality from COVID-19 - IDSA
Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome - The New England Journal of Medicine
Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19 - The New England Journal of Medicine
Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment - The New England Journal of Medicine
WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19 - World Health Organization (WHO)
Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection - The New England Journal of Medicine
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: a - The Lancet
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 - The New England Journal of Medicine
Extended nirmatrelvir–ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial - The Lancet
Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19 - The New England Journal of Medicine
Norvir (Ritonavir) for HIV: Dosage, Side Effects, and More - TheBody
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study - Nature
Association of nirmatrelvir–ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study - The Lancet
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in high-risk patients - Oxford Academic
COVID-19 Management With Paxlovid (Nirmatrelvir-Ritonavir) Effective in CKD - Vaccine Advisor
Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients - Oxford Academic
Nirmatrelvir-Ritonavir Shows No Outcome Benefit in Vaccinated High-Risk COVID-19 Patients: NEJM - Medical Dialogues
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial - The Lancet
Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in Beijing - Nature
VV116 or Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19 - The New England Journal of Medicine
Unexpected voriconazole toxicity due to nirmatrelvir/ritonavir: a case report on drug-drug interaction and the role of therapeutic drug monitoring - Frontiers
Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study - Nature
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study - The Lancet
Case Report: Nirmatrelvir/Ritonavir and Tacrolimus in a Kidney Transplant Recipient With COVID-19 - American Academy Of Family Physicians | AAFP
Adjusted green HPLC determination of nirmatrelvir and ritonavir in the new FDA approved co-packaged pharmaceutical dosage using supported computational calculations - Nature
Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies - Frontiers
Effects of Ritonavir-Boosted Darunavir vs Doravirine in Patients With HIV Infection - Infectious Disease Advisor
Dolutegravir noninferior to a ritonavir-boosted protease inhibitor regimen for treating HIV - 2 Minute Medicine
Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management - The Lancet
Darunavir/Ritonavir With Rifampicin May Be Hepatotoxic - Infectious Disease Advisor
Paxlovid (nirmatrelvir and ritonavir) for the Treatment of Covid-19 - Clinical Trials Arena
Could mechanochemistry have saved Abbott Laboratories $250 million? - Chemistry World
Development and validation of a RP-HPLC method for simultaneous determination of five COVID-19 antiviral drugs in pharmaceutical formulations - Nature
Dolutegravir plus darunavir superior to three-drug darunavir combination in second-line treatment - Aidsmap
Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials - Nature
Nirmatrelvir-ritonavir combination reduces hospitalization and mortality in COVID-19 - 2 Minute Medicine
Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19 - Frontiers
Nirmatrelvir/Ritonavir Regimen for Mild/Moderately Severe COVID-19: A Rapid Review With Meta-Analysis and Trial Sequential Analysis - Annals of Family Medicine
High rate of major drug–drug interactions of lopinavir–ritonavir for COVID-19 treatment - Nature
Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19 - The New England Journal of Medicine
Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir - Nature
Nirmatrelvir–Ritonavir Ineffective for Most Post-COVID Conditions - respiratory-therapy.com
Uptick in Paxlovid Shows No Clinical Benefit in Vaccinated Older Adults With COVID-19 - Vaccine Advisor
Foreign Language Equivalents
Foreign Language Equivalents of 'ritonavir'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
riitonavir,   ritonavr,   ritonvir,   ritoanvir,   ritobavir,   ritonsvir,   ritonaviir,   rionavir,   rtonavir,   rritonavir,   irtonavir,   ritonacir,   ritnavir,   ritpnavir,   rittonavir,   riotnavir,   rotonavir,   ritonvair,   ritoavir,   eitonavir,   titonavir,   ritonavie,   rironavir,   ritonavvir,   ritomavir,   ritonaivr,   ritonavirr,   ritonabir,   ritonair,   rtionavir,   ritonnavir,   ritonaavir,   ritonavur,   ritonavit,   ritonavri,   ritonavor,   ritinavir,   ritoonavir,   ritnoavir,   rutonavir,   ritonavi,   itonavir,   riyonavir
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z